Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMA VALLEE : revenue, balance sheet and financial ratios
PHARMA VALLEE is a French company
founded 10 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in MOUTIERS (73600),
this company of category PME
shows in 2025 a net income positive of 381 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-08-08
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
Synthèse
Santé financière :
Saine
Aucun signal de fragilité majeur : rentabilité positive et structure financière équilibrée.
In summary, PHARMA VALLEE posts positive profitability over the latest financial year. Its financial structure is fragile, with debt above sector norms — a point to monitor.
Revenue and income statement
In 2025, PHARMA VALLEE generates positive net income of 381 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2021-2025: 69 k€ -> 381 k€.
Net income (2025)
?
380 827 €
Loading income statement...
The detailed income statement is not available for this company (simplified accounts or confidential data).
Assets
Loading data...
Assets balance sheet data not available for this company
Liabilities
Loading data...
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 125%. This ratio is less favorable than the sector median (35.2%) and warrants attention. Financial autonomy (= Equity / Total assets x 100) reaches 40%. This ratio is less favorable than the sector median (58.9%) and warrants attention.
Debt ratio (2025)
?
125.47%
Financial autonomy (2025)
?
39.58%
Asset age ratio (2025)
?
4.3%
| Indicator |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
| Debt ratio |
614.62 |
348.722 |
213.84 |
184.14 |
125.988 |
92.567 |
68.521 |
52.652 |
125.475 |
| Financial autonomy |
12.297 |
20.15 |
28.601 |
31.203 |
39.492 |
46.714 |
52.705 |
59.791 |
39.579 |
| Repayment capacity |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Cash flow / Revenue |
None% |
None% |
None% |
None% |
None% |
None% |
None% |
None% |
None% |
Sector positioning
Q1: 10.81%
Med: 35.19%
Q3: 99.39%
Watch
+23 pts over 3 years
In 2025, the debt ratio of PHARMA VALLEE (125.5%) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
Q1: 41.22%
Med: 58.9%
Q3: 74.99%
Watch
-26 pts over 3 years
In 2025, the financial autonomy of PHARMA VALLEE (39.6%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 2.05. This ratio is more favorable than the sector median (1.8).
Liquidity ratio (2025)
?
2.05
| Indicator |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
| Liquidity ratio |
1.70539 |
2.16041 |
2.51709 |
2.22589 |
2.60575 |
2.9380200000000003 |
2.8920299999999997 |
3.4231 |
2.05234 |
| Interest coverage |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Sector positioning
Q1: 1.37
Med: 1.84
Q3: 2.63
Good
-19 pts over 3 years
In 2025, the liquidity ratio of PHARMA VALLEE (2.05) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Positioning of PHARMA VALLEE in its sector
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMA VALLEE is estimated at
6 049 482 €
(range 4 105 207€ - 9 492 470€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
6 049 482 €
Range: 4 105 207€ - 9 492 470€
NAF 5 année 2025
Valuation method used
Net Income Multiple
380 827 €
×
15.9x
=
6 049 482 €
Range: 4 105 207€ - 9 492 471€
Only this financial indicator is available for this company.
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
- EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
- Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
- Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Top companies in Commerce de détail de produits pharmaceutiques en magasin spécialisé
Largest companies by revenue in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé:
Frequently asked questions about PHARMA VALLEE
What is the revenue of PHARMA VALLEE ?
The revenue of PHARMA VALLEE is not publicly disclosed (confidential accounts filed with INPI).
Is PHARMA VALLEE profitable?
Yes, PHARMA VALLEE generated a net profit of 381 k€ in 2025.
Where is the headquarters of PHARMA VALLEE ?
The headquarters of PHARMA VALLEE is located in MOUTIERS (73600), in the department Savoie.
Where to find the tax return of PHARMA VALLEE ?
The tax return of PHARMA VALLEE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMA VALLEE operate?
PHARMA VALLEE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.